Tau Imaging in Parkinsonism: What Have We Learned So Far?
Tau Imaging in Parkinsonism: What Have We Learned So Far?
复制标题
帕金森病的 Tau 成像：到目前为止我们学到了什么？
DOI：
10.1002/mdc3.12584
复制
发表时间：
2018
影响因子：
4
通讯作者：
Whitwell,JenniferL
中科院分区：
文献类型：
--
作者：
Whitwell,JenniferL
BackgroundPositron emission tomography配体，现在可以结合到tau蛋白在大脑中，提供了令人兴奋的机会，以评估在活体patients.MethodsThis手稿的存在和分布的tau蛋白在体内进行了系统的审查研究，已经进行了tau PET成像帕金森病患者。PubMed检索截至2017年11月13日，综述包括病例报告和患者对照研究。结果大多数tau‐PET研究使用[18 F]AV‐1451配体，少数使用[11 C] PBB 3和[18 F]THK‐5351配体。在帕金森病痴呆和路易体痴呆中观察到皮质tau‐PET摄取升高，推测与阿尔茨海默病相关病理学有关。在进行性核上性麻痹的皮质下结构和皮质基底综合征的皮质下结构和运动皮质中观察到轻度的tau-PET摄取模式，尽管与放射自显影研究的差异显示缺乏与4重复tau的结合和在皮质下结构中观察到的“脱靶”结合限制了对这些发现的解释。在tau突变的额颞叶痴呆中的发现是可变的，但信号升高在3和4重复tau沉积的突变中最明显。在多系统萎缩症（synucleinopathy.ConclusionThe当前一代的tau‐PET配体的价值因帕金森综合征而异，取决于tau病理学和“脱靶”结合的潜在变异性。需要更多的工作来了解结合的生物学基础，并且需要更特异性的tau PET配体来研究帕金森病。
BackgroundPositron emission tomography ligands are now available that bind to tau proteins in the brain, providing the exciting opportunity to assess the presence and distribution of tau in vivo in living patients.MethodsThis manuscript performed a systematic review of studies that have performed tau PET imaging in patients with parkinsonian disorders. PubMed was searched through November 13, 2017 and the review included case reports and patient‐control studies.ResultsMost tau‐PET studies have utilized the [18F]AV‐1451 ligand, with a few using the [11C]PBB3 and [18F]THK‐5351 ligands. Elevated cortical tau‐PET uptake has been observed in Parkinson's disease dementia and dementia with Lewy bodies, presumed to be related to Alzheimer's disease‐related pathology. Mild patterns of tau‐PET uptake have been observed in subcortical structures in progressive supranuclear palsy and subcortical structures and motor cortex in corticobasal syndrome, although discrepancy with autoradiographic studies that show lack of binding to 4‐repeat tau and “off‐target” binding observed in subcortical structures limit the interpretation of these findings. Findings in frontotemporal dementia with tau mutations are variable, but elevated signal is most pronounced in mutations with deposition of both 3 and 4‐repeat tau. Elevated tau‐PET uptake has also been observed in multiple system atrophy, a synucleinopathy.ConclusionThe value of the current generation of tau‐PET ligands varies across parkinsonian syndromes, depending upon underlying variability in tau pathology and “off‐target” binding. More work is needed to understand the biological basis of binding and more specific tau PET ligands are needed to study parkinsonian disorders.
登录
查看更多内容
影响因子：
9.9
作者：
S. Spina;Daniel R. Schonhaut;B. Boeve;W. Seeley;R. Ossenkoppele;J. O’Neil;Andreas Lazaris;H. Rosen;A. Boxer;D. Perry;B. Miller;D. Dickson;J. Parisi;W. Jagust;M. Murray;G. Rabinovici
通讯作者：
S. Spina;Daniel R. Schonhaut;B. Boeve;W. Seeley;R. Ossenkoppele;J. O’Neil;Andreas Lazaris;H. Rosen;A. Boxer;D. Perry;B. Miller;D. Dickson;J. Parisi;W. Jagust;M. Murray;G. Rabinovici
影响因子：
3.4
作者：
Fowler, JS;Logan, J;Volkow, ND
通讯作者：
Volkow, ND
影响因子：
8.6
作者：
Hansen, Allan K.;Damholdt, Malene Flensborg;Borghammer, Per
通讯作者：
Borghammer, Per
影响因子：
14
作者：
Sander, Kerstin;Lashley, Tammaryn;Arstad, Erik
通讯作者：
Arstad, Erik
进行性核上性麻痹患者基底神经节 18 F-AV-1451 结合增加
影响因子：
8.6
作者：
Ruben Smith;M. Schain;C. Nilsson;O. Strandberg;Tomas G. Olsson;Douglas Hägerström;Jonas Jögi;E. Borroni;M. Schöll;M. Honer;O. Hansson
通讯作者：
O. Hansson